BWV - Blue Water AbVacc team up to develop vaccines for Monkeypox Marburg virus

• Blue Water Vaccines ( NASDAQ: BWV ) is collaborating with AbVacc to jointly develop vaccine candidates targeting monkeypox and Marburg virus disease (MVD).
• The companies said that both vaccines will utilize BWV's norovirus shell and protrusion ((S&P)) virus-like particle (VLP) platform, which allows for the presentation of multiple antigens on the surface of either the S or P particle of a norovirus backbone.
• BWV previously announced plans to explore a novel monkeypox vaccine candidate using this platform and under this agreement, the companies plan to work to optimize the vaccine design and conduct preclinical immunogenicity and efficacy studies.
• In addition to monkeypox vaccine, AbVacc will use its expertise in MVD to develop a novel vaccine targeting Marburg virus using BWV's VLP platform, the companies noted .
• AbVacc is a spin-off of Integrated BioTherapeutics, BWV noted.

For further details see: